-
Product Insights
Poly – Drugs In Development, 2023
Global Markets Direct’s Poly provides in depth analysis on Poly targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly targeted therapeutics development and features dormant and discontinued...
-
Product Insights
Poly [ADP Ribose] Polymerase 2 – Drugs In Development, 2023
Global Markets Direct’s Poly [ADP Ribose] Polymerase 2 provides in depth analysis on Poly [ADP Ribose] Polymerase 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly...
-
Product Insights
Poly [ADP Ribose] Polymerase 1 – Drugs In Development, 2023
Global Markets Direct’s Poly [ADP Ribose] Polymerase 1 provides in depth analysis on Poly [ADP Ribose] Polymerase 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly...
-
Product Insights
Poly [ADP Ribose] Polymerase 3 – Drugs In Development, 2023
Global Markets Direct’s Poly [ADP Ribose] Polymerase 3 provides in depth analysis on Poly [ADP Ribose] Polymerase 3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RP-12146 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-12146 in Breast Cancer Drug Details: RP-12146 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Triple-Negative Breast Cancer (TNBC) Drug Details: Ampligen...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Prostate Cancer Drug Details: Ampligen is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Melanoma Drug Details: Ampligen is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Metastatic Colorectal Cancer Drug Details: Ampligen is under development...